Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2025-12-24 @ 4:21 PM
NCT ID:
NCT06607666
Eligibility Criteria:
Inclusion Criteria:
* patients diagnosed for acromegaly;
* patients underwent first line treatment for acromegaly with pituitary surgery;
* patients with acromegaly diagnosis confirmed through the pathological examination of the resected pituitary tumor;
* patients affected by persistently active acromegaly, after pituitary surgery and consecutively treated with Lanreotide ATG at standard dose;
* patients treated with Lanreotide ATG at standard dose for at least 12 consecutive months and/or patients treated with Lanreotide ATG at standard dose for 6 consecutive months and then at high dose/frequency for at least 12 consecutive month;
* cases with available of all data, required for this study in internal database.
Exclusion Criteria:
* patients underwent medical therapies or radiotherapy before pituitary surgery;
* patients underwent radiotherapy within 3 years before starting the treatment with Lanreotide ATG;
* patients on treatment with other drugs for acromegaly as dopamine agonist and/or antagonist of GH receptor.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06607666
Study Brief:
Protocol Section:
NCT06607666